Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in higher-risk myelodysplastic syndromes (Chinese patients)
CTR20132547Phase 2Completed
- Sponsor
- Tigermed
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), myelodysplastic syndrome with excess blasts (MDS-EB), refractory anemia with excess blasts in transformation (RAEB-T), chronic myelomonocytic leukemia (CMML), sponsored by Tigermed. Started Feb 2014; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic syndrome with excess blasts (MDS-EB)refractory anemia with excess blasts in transformation (RAEB-T)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on CTR20132547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132547.